Does Wegovy Increase Testosterone Levels?

Step 1, Understanding why obesity and low testosterone are connected

Testosterone is produced mainly in the testes in men and in smaller quantities in the ovaries and adrenal glands in women. In people carrying excess body fat, adipose tissue contains high concentrations of aromatase, an enzyme that converts testosterone into oestradiol (a form of oestrogen). The more adipose tissue present, the greater this conversion. The net result is lower circulating testosterone and, in men, a pattern sometimes called obesity-related hypogonadism.

There is also a feedback loop. Low testosterone makes it harder to maintain muscle mass and easier to accumulate fat, which in turn suppresses testosterone further. Breaking into that cycle is one reason why clinicians pay attention to hormonal changes in patients who lose significant weight, regardless of how that loss is achieved.

For men who are curious about their own baseline, a simple check worth doing before any appointment is noting whether you have recently had a blood test that included total testosterone. Many GPs include it in a standard metabolic panel if you ask. Knowing your starting point makes any future comparison meaningful. The Wegovy overview page has more on who the medicine is licensed for and how treatment is structured.

Step 2, What semaglutide actually does, and what it does not do

Semaglutide, the active ingredient in Wegovy, is a GLP-1 receptor agonist. It mimics a gut hormone released after eating, reducing appetite, slowing gastric emptying, and helping people eat less without feeling deprived. Its licensed purpose is weight management alongside a reduced-calorie diet and increased physical activity, as described on the weight-loss treatments page.

There is no evidence in the published literature that semaglutide binds to androgen receptors or directly stimulates testosterone synthesis. When researchers observe testosterone rising in men on GLP-1 therapy, the change correlates with the degree of weight loss, not with the dose of the medicine or its duration of action in isolation. A 2023 analysis published in peer-reviewed literature found that men with obesity and type 2 diabetes who lost weight on semaglutide showed improvements in total testosterone, but those improvements tracked closely with the reduction in body mass index rather than appearing as a drug-specific effect. The NHS semaglutide medicine page sets out the medicine's known actions and side effects clearly.

In practical terms, this matters because it tempers expectations in both directions. Wegovy is not a testosterone treatment, and men with clinically diagnosed hypogonadism should discuss testosterone management separately with their GP or endocrinologist.

Step 3, What the evidence suggests for men and for women separately

For men with obesity and low or borderline testosterone, the evidence is reasonably encouraging. Small-to-moderate improvements in total testosterone have been reported after weight losses of 10% or more of body weight, consistent with what GLP-1 medicines can produce. The STEP 1 trial in the New England Journal of Medicine reported an average weight reduction of around 15% at 68 weeks with semaglutide 2.4mg alongside lifestyle changes. That scale of loss, if replicated in the real world, is the range at which clinically meaningful hormonal shifts tend to appear in the research. Individual results vary, and whether testosterone normalises fully depends on factors like age, the severity of obesity, and whether other conditions are present.

For women, testosterone physiology is different. Women with PCOS often have elevated androgens, and weight loss (achieved by any means) is associated with a reduction in androgen excess, which can improve symptoms such as irregular periods and excess hair growth. Whether Wegovy produces greater androgen-related improvements than equivalent weight loss achieved through diet alone is not yet established from robust comparative data. Women without PCOS who are premenopause or postmenopause may see modest changes in androgen levels secondary to weight loss, but these are generally not clinically significant in either direction. If you have questions about Wegovy's effects alongside other medicines or hormonal conditions, the effect of Wegovy on cholesterol page illustrates how the service approaches similar secondary metabolic effects, through a thorough clinical assessment rather than assumptions.

One note on dose: results in trials scale with the amount of weight lost, and that in turn reflects the maintenance dose reached and how long someone stays on treatment. If you are wondering whether increasing your Wegovy dose actually leads to more weight loss, that question is addressed in detail in a dedicated guide. How dose increases are managed in practice is covered in the Wegovy dose increase guide.

Step 4, What this means if testosterone is one of your reasons for considering Wegovy

Wegovy is licensed for weight management, not for raising testosterone. A prescriber at nume (sorry, at a regulated online pharmacy) cannot prescribe Wegovy with testosterone improvement as the stated clinical goal. What a clinician can do is assess your full picture: your weight, your BMI, any weight-related conditions (including conditions associated with low testosterone, such as metabolic syndrome), and whether you meet the criteria for treatment.

If weight loss through a programme that includes Wegovy subsequently improves your testosterone, that is a welcome secondary effect, and one worth monitoring with your GP through periodic blood tests. It is not guaranteed, and the prescriber's role is to help you lose weight safely, not to optimise hormone panels directly. For anyone considering treatment, our clinical team reviews every consultation personally, no automated decisions. If testosterone is a specific concern, raising it with your GP before or during treatment means it can be tracked properly. You can read about how a Wegovy increase works and what to expect at each stage of the dose schedule on the dedicated page, and see the full structure from the start on the Wegovy doses page.